For more than a decade, CRISPR’s basic syntax seemed fixed: a guide RNA led a Cas enzyme to its target, usually a stretch of DNA. But papers published in Nature Biotechnology in May 2026 challenge that rule at a fundamental level. Researchers showed that certain Cas12 systems can be loaded with synthetic pseudo-guide DNA, or ΨDNA, rather than RNA; even more strikingly, that chemical substitution appears to redirect the machinery toward RNA targets. A companion structural study found that DNA-guided Cas12a can still assemble a catalytically competent complex, with PAM-dependent engagement helping to enable RNA recognition and cleavage. In other words, the supposedly indispensable “RNA guide” may turn out to be a historical convention, not a biological inevitability. (nature.com)
The practical implications are substantial. RNA is the cell’s working draft rather than its permanent archive, so targeting RNA offers a way to modulate gene output without immediately rewriting the genome itself. In human cells, the ΨDNA–AsCas12a platform reduced endogenous mRNA levels, supported multiplex knockdown of several transcripts, and was adapted for functions such as RNase H1 recruitment and targeted RNA methylation. The same study also reported simultaneous DNA-and-RNA targeting with a single CRISPR effector, raising the possibility of experiments that compare immediate transcript-level consequences with slower genomic ones in the same system. That would shift CRISPR from a one-shot editor into something more layered: a tool for intervention, timing, and control. (nature.com)
Still, a conceptual breakthrough is not the same as a finished therapeutic platform. The structural paper explicitly describes current DNA-guided Cas12a activity in cells as modest and frames the method as proof of concept rather than a mature technology. Yet the attraction is obvious: DNA guides are generally more stable and easier to manufacture than RNA guides, and the accompanying commentary argues that guide DNA genuinely expands the CRISPR toolkit. If efficiency improves, the consequences could reach well beyond gene editing in the narrow sense, extending to transient RNA knockdown, antiviral strategies, live-cell RNA imaging, and more accessible diagnostics. The deepest change, then, is philosophical: CRISPR may no longer be only a way to rewrite life’s blueprint, but also a way to revise its fleeting, error-prone drafts. (nature.com)
